Consolidated Statement Of Cash Flows

Kidswell Bio Corporation - Filing #7324937

Concept As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
As at
2022-03-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-1,420,527,000 JPY
-656,224,000 JPY
Depreciation
921,000 JPY
932,000 JPY
Interest and dividend income
-8,000 JPY
-12,000 JPY
Interest expenses
35,651,000 JPY
32,760,000 JPY
Subtotal
-422,474,000 JPY
-1,381,999,000 JPY
Decrease (increase) in trade receivables
207,359,000 JPY
-626,912,000 JPY
Income taxes paid
-1,210,000 JPY
-1,210,000 JPY
Decrease (increase) in inventories
-240,337,000 JPY
353,498,000 JPY
Net cash provided by (used in) operating activities
-453,634,000 JPY
-1,421,259,000 JPY
Increase (decrease) in trade payables
-70,423,000 JPY
110,084,000 JPY
Other, net
-82,501,000 JPY
127,006,000 JPY
Interest and dividends received
8,000 JPY
12,000 JPY
Interest paid
-29,958,000 JPY
-38,062,000 JPY
Cash flows from investing activities
Purchase of investment securities
JPY
-50,000,000 JPY
Net cash provided by (used in) investing activities
JPY
-28,825,000 JPY
Cash flows from financing activities
Purchase of treasury shares
0 JPY
0 JPY
Proceeds from long-term borrowings
1,000,000,000 JPY
970,000,000 JPY
Repayments of long-term borrowings
-375,000,000 JPY
-150,000,000 JPY
Net cash provided by (used in) financing activities
1,617,883,000 JPY
1,356,312,000 JPY
Net increase (decrease) in cash and cash equivalents
1,164,249,000 JPY
-93,772,000 JPY
Cash and cash equivalents
2,231,411,000 JPY
1,067,162,000 JPY
1,160,934,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.